Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Arvinas news
05.05.2022
Arvinas' GAAP loss for the 3 months of 2022 was $63.4 million, up 54.6% from $41 million in the previous year. Revenue increased 4.4 times to $24.2 million from $5.5 million a year earlier.
Source: 
ir.arvinas.com
ir.arvinas.com
General information
| Company name | Arvinas |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 5 Science Park 395 Winchester Avenue New Haven, CT 06511 United States |
| Mailing address | 5 Science Park 395 Winchester Avenue New Haven, CT 06511 United States |
| Website | ir.arvinas.com |
English (US) 